588 related articles for article (PubMed ID: 33113309)
1. No-Fault Compensation for Vaccine Injury - The Other Side of Equitable Access to Covid-19 Vaccines.
Halabi S; Heinrich A; Omer SB
N Engl J Med; 2020 Dec; 383(23):e125. PubMed ID: 33113309
[No Abstract] [Full Text] [Related]
2. A Viral Pandemic, Vaccine Safety, and Compensation for Adverse Events.
Meissner HC
JAMA; 2021 Feb; 325(8):721-722. PubMed ID: 33544127
[No Abstract] [Full Text] [Related]
3. Covid-19 Vaccine Injuries - Preventing Inequities in Compensation.
Van Tassel K; Shachar C; Hoffman S
N Engl J Med; 2021 Mar; 384(10):e34. PubMed ID: 33471973
[No Abstract] [Full Text] [Related]
4. COVAX no fault compensation program for COVID-19 vaccine injuries in 92 low and middle income countries.
Mazur A; Benitez S; Chuffart-Finsterwald S; La Rotta R; Hampton LM
Vaccine; 2021 Dec; 39(49):7128-7130. PubMed ID: 34732277
[No Abstract] [Full Text] [Related]
5. [Covid-19 vaccination and risk of anaphylaxis - Recommendations for practical management].
Worm M; Ring J; Klimek L; Jakob T; Lange L; Treudler R; Beyer K; Werfel T; Biedermann T; Bircher A; Fischer M; Fuchs T; Heller AR; Hoffmann F; Huttegger I; Kopp MV; Kugler C; Lommatzsch M; Pfaar O; Rietschel E; Rueff F; Schnadt S; Seifert R; Stöcker B; Vogelberg C; Sitter H; Gieler U; Brockow K
MMW Fortschr Med; 2021 Jan; 163(1):48-51. PubMed ID: 33464512
[No Abstract] [Full Text] [Related]
6. In favour of a bespoke COVID-19 vaccines compensation scheme.
Fairgrieve D; Holm S; Howells G; Kirchhelle C; Vanderslott S
Lancet Infect Dis; 2021 Apr; 21(4):448-450. PubMed ID: 33548195
[No Abstract] [Full Text] [Related]
7. Emergency Use Authorization of Covid Vaccines - Safety and Efficacy Follow-up Considerations.
Krause PR; Gruber MF
N Engl J Med; 2020 Nov; 383(19):e107. PubMed ID: 33064383
[No Abstract] [Full Text] [Related]
8. A review of China's compensation program for adverse reactions following immunization.
Yingxiong W
Front Public Health; 2023; 11():1211976. PubMed ID: 37608980
[TBL] [Abstract][Full Text] [Related]
9. Vaccine injury compensation: the Israeli case.
Kamin-Friedman S; Davidovitch N
Isr J Health Policy Res; 2021 Sep; 10(1):54. PubMed ID: 34517920
[TBL] [Abstract][Full Text] [Related]
10. COVID-19 Vaccine Injury Compensation Program: Lessons Learned From a Review of 10 Implementing Countries.
Kang CR; Choe YJ; Yoon SJ
J Korean Med Sci; 2024 Apr; 39(13):e121. PubMed ID: 38599598
[TBL] [Abstract][Full Text] [Related]
11. "When Will
Bloom BR; Nowak GJ; Orenstein W
N Engl J Med; 2020 Dec; 383(23):2202-2204. PubMed ID: 32897660
[No Abstract] [Full Text] [Related]
12. Equitable access to COVID-19 vaccination: a distant dream?
Lomazzi M; De Sousa L; Amofah G; Ricciardi W
Eur J Public Health; 2020 Dec; 30(6):1039-1040. PubMed ID: 33027515
[No Abstract] [Full Text] [Related]
13. Preparing for a COVID-19 Vaccine: How Can Nurses Change the Conversation.
Sullivan-Marx E
Nurs Outlook; 2020; 68(6):693-695. PubMed ID: 33243409
[No Abstract] [Full Text] [Related]
14. COVID-19 VACCINE IS HERE!!!
Erhabor GE
West Afr J Med; 2020 Dec; 37(7):712-713. PubMed ID: 33296475
[TBL] [Abstract][Full Text] [Related]
15. Status of vaccine development for COVID-19.
Mendes A
Br J Community Nurs; 2020 Dec; 25(12):620-621. PubMed ID: 33275511
[No Abstract] [Full Text] [Related]
16. No-fault compensation schemes for COVID-19 medical products.
Fujiwara Y; Onda Y; Hayashi S
Lancet; 2021 May; 397(10286):1707-1708. PubMed ID: 33965083
[No Abstract] [Full Text] [Related]
17. Global landscape analysis of no-fault compensation programmes for vaccine injuries: A review and survey of implementing countries.
Mungwira RG; Guillard C; Saldaña A; Okabe N; Petousis-Harris H; Agbenu E; Rodewald L; Zuber PLF
PLoS One; 2020; 15(5):e0233334. PubMed ID: 32437376
[TBL] [Abstract][Full Text] [Related]
18. Thrombosis after covid-19 vaccination.
Hunter PR
BMJ; 2021 Apr; 373():n958. PubMed ID: 33853865
[No Abstract] [Full Text] [Related]
19. Vaccinating the UK against covid-19.
Majeed A; Molokhia M
BMJ; 2020 Nov; 371():m4654. PubMed ID: 33257346
[No Abstract] [Full Text] [Related]
20. Opinion: For now, it's unethical to use human challenge studies for SARS-CoV-2 vaccine development.
Kahn JP; Henry LM; Mastroianni AC; Chen WH; Macklin R
Proc Natl Acad Sci U S A; 2020 Nov; 117(46):28538-28542. PubMed ID: 33122444
[No Abstract] [Full Text] [Related]
[Next] [New Search]
